TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-Like Ligand 1A (Anti-TL1A) in Adults With Moderately to Severely Active Ulcerative Colitis

Authors
Category Primary study
JournalAmerican Journal of Gastroenterology
Year 2024
This article has no abstract
Epistemonikos ID: d5ec49eda0c0a85fd45536f7dab7189728d50812
First added on: Feb 19, 2025